Anal canal carcinoma
disease diseaseOn this page
Also known as anal canal and perianal gland canceranal canal and perianal gland carcinomaanal canal cancercarcinoma of anal canalcarcinoma of the anal canal
Summary
Anal canal carcinoma (MONDO:0007108) is a cancer (an umbrella term covering 5 Mondo subtypes) and 24 clinical trials. Top therapeutic interventions include mitomycin. A subtype of anal canal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anal canal carcinoma |
| Mondo ID | MONDO:0007108 |
| OMIM | 105580 |
| Orphanet | 424013 |
| DOID | DOID:6126 |
| NCIT | C7489 |
| SNOMED CT | 285310000 |
| UMLS | C0563211 |
| MedGen | 107559 |
| GARD | 0021772 |
| Anatomy (UBERON) | UBERON:0000159 |
| Is cancer (heuristic) | yes |
Also known as: anal canal and perianal gland cancer · anal canal and perianal gland carcinoma · anal canal cancer · anal canal carcinoma · carcinoma of anal canal · carcinoma of the anal canal
Disease family
This is a subtype of anal canal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › intestinal cancer › anal canal cancer › anal canal carcinoma
Subtypes (5): anal canal adenocarcinoma, anal canal neuroendocrine neoplasm, cloacogenic carcinoma, anal canal squamous cell carcinoma, anal canal carcinoma in situ
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 14 |
| Not specified | 8 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05374252 | PHASE3 | UNKNOWN | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients |
| NCT02185443 | PHASE2 | RECRUITING | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases |
| NCT02314169 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer |
| NCT02701088 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life |
| NCT03403465 | PHASE2 | ACTIVE_NOT_RECRUITING | Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers |
| NCT05040815 | PHASE2 | RECRUITING | Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer |
| NCT06640283 | PHASE2 | RECRUITING | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes |
| NCT00754078 | PHASE2 | UNKNOWN | A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy |
| NCT01843452 | PHASE2 | TERMINATED | Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal |
| NCT02402842 | PHASE2 | COMPLETED | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma |
| NCT02437851 | PHASE2 | COMPLETED | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection |
| NCT02560298 | PHASE2 | UNKNOWN | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer |
| NCT03439085 | PHASE2 | TERMINATED | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers |
| NCT03946358 | PHASE2 | COMPLETED | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) |
| NCT05060471 | PHASE2 | COMPLETED | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients |
| NCT01858025 | EARLY_PHASE1 | COMPLETED | Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma |
| NCT04221893 | Not specified | RECRUITING | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers |
| NCT07059442 | Not specified | NOT_YET_RECRUITING | Screening for Anal Cancer and Precancer in Women With HIV (SANCA) |
| NCT01325961 | Not specified | COMPLETED | Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers |
| NCT01845779 | Not specified | COMPLETED | Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal |
| NCT03465501 | Not specified | COMPLETED | Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates |
| NCT03731754 | Not specified | UNKNOWN | Cross Closure for Reconstructing the Perineal Wound of Abdominoperineal Resection |
| NCT03942900 | Not specified | WITHDRAWN | Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma |
| NCT04626466 | Not specified | COMPLETED | Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MITOMYCIN | 4 | 3 |
Related Atlas pages
- Drugs: Mitomycin